By Priyabrata Pattnaik, PhD and George Adams
Volume 12, Issue 3 (Fall 2013)
There are approximately 400 vaccines in commercial manufacture targeted at 24 infectious diseases. Of these vaccines, about 300 are viral-based. It is estimated that 1400 vaccines are in development, half of which are viral-based (~ 640 viral vaccines, ~ 200 viral vectors, ~ 60 virus-like particles). Another 240 gene therapy products are in development that utilize the same viral-based technology. A live vector vaccine is one that uses a weakened or harmless microorganism to transport antigenic viral pieces into a cell in order to stimulate an immune response. Vectored vaccines show promise in reliably inducing potent cell-mediated immunity, which is essential for complex diseases such as AIDS, malaria, and cancer…
Citation: Pattnaik P, Adams G. Expediting Clinical Batch Production of Viral-Vectored Vaccines and Gene Therapy Products. BioProcess J, 2013; 12(3): 41-45. https://dx.doi.org/10.12665/J123.Pattnaik
Posted online September 30, 2013